ICCC · Immucell Corp /De/
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-18 | te Boekhorst Paul Francis Olivier |
Director, President and CEO |
Buy↑
|
Common Stock, par value $.01 per share
|
8,000 |
| 2026-04-15 | Wainman Paul R |
Director |
Award↑
Filing footnotes — Non Qualified Stock Options (Right to buy) (Direct)
The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029. |
Non Qualified Stock Options (Right to buy)
|
11,933 |
| 2026-04-15 | Basse Gloria F |
Director |
Award↑
Filing footnotes — Non Qualified Stock Options (Right to buy) (Direct)
The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029. |
Non Qualified Stock Options (Right to buy)
|
11,933 |
| 2026-04-15 | Turner Kathy V |
Director |
Award↑
Filing footnotes — Non Qualified Stock Options (Right to buy) (Direct)
The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029. |
Non Qualified Stock Options (Right to buy)
|
17,899 |
| 2026-04-15 | Tomsche David Scott |
Director |
Award↑
Filing footnotes — Non Qualified Stock Options (Right to buy) (Direct)
The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029. |
Non Qualified Stock Options (Right to buy)
|
11,933 |
| 2026-04-01 | Turner Kathy V |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-03-20 | BRIGHAM MICHAEL F |
Director |
Tax↓
Filing footnotes — Common Stock, par value $.01 per share (Direct)
Number of shares surrendered to the Issuer in payment of the exercise price of the option. |
Common Stock, par value $.01 per share
|
24,052 |
| 2026-03-20 | BRIGHAM MICHAEL F |
Director |
Convert↑
Filing footnotes — Common Stock, par value $.01 per share (Direct)
Number of shares resulting from stock-for-stock exercise of stock option. The Reporting Person surrendered previously owned shares in full payment of the exercise price for that option. |
Common Stock, par value $.01 per share
|
25,000 |
| 2026-03-20 | BRIGHAM MICHAEL F |
Director |
Convert↓
|
Stock Options (right to buy)
|
25,000 |
| 2026-01-27 | te Boekhorst Paul Francis Olivier |
Director, President and CEO |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
This amendment amends the previously reported transaction effective on 1/27/2026 to disclose the correct number of shares included in the option award. Option grant made to Mr. te Boekhorst in connection with his employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as nonqualified stock option. One hundred percent of the stock option will vest when the Issuer's net operating income for four consecutive calendar quarters equals or exceeds 300% of the Issuer's audited net operating income for its 2025 fiscal year. |
Stock Options (right to buy)
|
109,500 |
| 2026-01-27 | Fiori Timothy C |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Option grant made to Mr. Fiori in connection with his employment as Chief Financial Officer. The option shall be treated as an incentive stock option to the maximum extent permitted by the International Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 40,000 options on the first, second and third anniversary of the grant date. |
Stock Options (right to buy)
|
120,000 |
| 2026-01-27 | Brockmann Bobbi Jo |
Director, VP of Sales and Marketing |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Option grant made to Ms. Brockmann in connection with her employment as Vice President of Sales and Marketing. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 33,333 shares becoming exercisable on each of January 27, 2027 and January 27, 2028 and 33,334 shares becoming exercisable on January 27, 2029. |
Stock Options (right to buy)
|
100,000 |
| 2025-12-04 | te Boekhorst Paul Francis Olivier |
Director, President and CEO |
Buy↑
Filing footnotes — Common Stock $0.10 par value per share (Direct)
This amendment amends the previously reported transaction effective on 12/3 to disclose the correct amount and price of shares purchased, and the correct transaction date. |
Common Stock $0.10 par value per share
|
2,432 |
| 2025-12-03 | te Boekhorst Paul Francis Olivier |
Director, President and CEO |
Buy↑
Filing footnotes — Common Stock $0.10 par value per share (Direct)
This amendment amends the previously reported transaction effective on 12/3 to disclose the correct amount and price of shares purchased. |
Common Stock $0.10 par value per share
|
3,598 |
| 2025-11-25 | Tomsche David Scott |
Director |
Buy↑
|
Common Stock $0.10 par value per share
(I)
|
1,633 |
| 2025-11-25 | Tomsche David Scott |
Director |
Buy↑
|
Common Stock $0.10 par value per share
|
1,633 |
| 2025-11-07 | te Boekhorst Paul Francis Olivier |
Director, President and CEO |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Option grant made to Mr. te Boekhorst in connection with his commencement of employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 24,759 options on the first, second, and third anniversary of the grant date. |
Stock Options (right to buy)
|
74,277 |
| 2025-06-12 | Gathagan Bryan K. |
Director |
Buy↑
|
Common stock $0.10 per value per share
|
1,000 |
| 2025-06-11 | Basse Gloria F |
Director |
Convert↓
Filing footnotes — Non Qualified Stock Options (Right to buy) (Direct)
(2) Original stock option was for 15,000 shares. These shares resulted from a net exercise transaction, with 11,470 shares withheld (credited at $6.29 per share, the closing price of the Common stock on the date of exercise) in payment of the exercise price for 3,530 shares. |
Non Qualified Stock Options (Right to buy)
|
3 |
| 2025-06-11 | Basse Gloria F |
Director |
Convert↓
Filing footnotes — Non Qualified Stock Options (Right to buy) (Direct)
(2) Original stock option was for 15,000 shares. These shares resulted from a net exercise transaction, with 11,470 shares withheld (credited at $6.29 per share, the closing price of the Common stock on the date of exercise) in payment of the exercise price for 3,530 shares. |
Non Qualified Stock Options (Right to buy)
|
11,470 |
| 2025-06-11 | Basse Gloria F |
Director |
Convert↑
Filing footnotes — Common stock $0.10 per value per share (Direct)
(1) Shares acquired in stock option net exercise transaction with the Issuer. |
Common stock $0.10 per value per share
|
3,530 |
| 2025-04-16 | Tomsche David Scott |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2025-04-16 | Rosgen Steven T. |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2025-04-16 | Fiori Timothy C |
Director, Chief Financial Officer |
Award↑
|
Incentive Stock Options (Right to buy)
|
30,000 |
| 2025-04-16 | Gathagan Bryan K. |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2025-04-16 | Wainman Paul R |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2025-04-16 | Basse Gloria F |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2025-04-16 | Brockmann Bobbi Jo |
Director, VP of Sales and Marketing |
Award↑
|
Incentive Stock Options (Right to buy)
|
5,000 |
| 2025-04-07 | Fiori Timothy C |
Director, Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-09-20 | Tomsche David Scott |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2024-09-20 | Rosgen Steven T. |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2024-09-20 | Wainman Paul R |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2024-09-20 | Gathagan Bryan K. |
Director |
Award↑
|
Non-Qualified Stock Options (Right to buy)
|
10,000 |
| 2024-09-20 | Basse Gloria F |
Director |
Award↑
|
Non Qualified Stock Options (Right to buy)
|
10,000 |
| 2024-08-28 | Tomsche David Scott |
Director |
Other↑
Filing footnotes — Common stock $0.10 per value per share (Direct)
(1) This figure includes 6,987 shares of common stock held by immediate family members of Dr. Tomsche. |
Common stock $0.10 per value per share
|
2,186 |
| 2024-08-23 | Tomsche David Scott |
Director |
Other↑
Filing footnotes — Common stock $0.10 per value per share (Direct)
(1) This figure includes 6,987 shares of common stock held by immediate family members of Dr. Tomsche. |
Common stock $0.10 per value per share
|
6,005 |
| 2024-08-22 | Tomsche David Scott |
Director |
Other↑
Filing footnotes — Common stock $0.10 per value per share (Direct)
(1) This figure includes 6,987 shares of common stock held by immediate family members of Dr. Tomsche. |
Common stock $0.10 per value per share
|
10,000 |
| 2024-08-19 | Tomsche David Scott |
Director |
Other↑
Filing footnotes — Common stock $0.10 per value per share (Direct)
1. This figure includes 6,987 shares of common stock held by immediate family members of Dr. Tomsche. |
Common stock $0.10 per value per share
|
3,172 |
| 2024-08-16 | Tomsche David Scott |
Director |
Other↑
|
Common stock $0.10 per value per share
|
4,811 |
| 2024-08-15 | Tomsche David Scott |
Director |
Other↑
|
Common stock $0.10 per value per share
|
2,017 |
| 2023-09-06 | Tomsche David Scott |
Director |
Other↑
Filing footnotes — Common stock $0.10 per value per share (Direct)
1. This figure includes 6,987 shares of common stock held by immediate family members of Dr. Tomsche. |
Common stock $0.10 per value per share
|
3,100 |
| 2023-06-28 | Gathagan Bryan K. |
Director |
Award↑
|
Non-Qualified Stock Options (Right to buy)
|
15,000 |
| 2023-06-16 | Gathagan Bryan K. |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2023-03-14 | Tomsche David Scott |
Director |
Other↑
|
Common Stock, $0.10 per value per share
|
69 |
| 2023-03-14 | Tomsche David Scott |
Director |
Other↑
|
Common Stock, $0.10 per value per share
|
31 |
| 2023-03-14 | Tomsche David Scott |
Director |
Other↑
|
Common Stock, $0.10 per value per share
|
31 |
| 2023-03-14 | Tomsche David Scott |
Director |
Other↑
|
Common Stock, $0.10 per value per share
|
100 |
| 2023-03-14 | Tomsche David Scott |
Director |
Other↑
|
Common Stock, $0.10 per value per share
|
31 |
| 2023-03-14 | Tomsche David Scott |
Director |
Other↑
|
Common Stock, $0.10 per value per share
|
69 |
| 2023-03-14 | Tomsche David Scott |
Director |
Other↑
|
Common Stock, $0.10 per value per share
|
69 |